Screening for subclinical complications in young type 1 diabetic patients: Experience acquired in Brussels

Pediatric Endocrinology Reviews

Volumn 1, Issue 4, 2004, Pages 380-403

  Dorchy, Harry ^a  

^a HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

Author keywords

C reactive protein; Complement; Diabetic children; Diabetic complications; Glycolytic activity; Helicobacter pylori; Lipoprotein (a); Lipoproteins; Nephropathy; Neuropathy; Obesity; Oxidative stress; Retinopathy; Triiodothyronine; Type 1 diabetes; Well being

Indexed keywords

ALBUMIN; APOLIPOPROTEIN B; ASCORBIC ACID; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CHOLESTEROL; COMPLEMENT; FLUORESCEIN; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLYCOSAMINOGLYCAN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; ISOPHANE INSULIN A; LIOTHYRONINE; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM; MONOCOMPONENT INSULIN; MONOTARD MC; NEUTRAL INSULIN; PROTAPHANE HM; TRANSFERRIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ADOLESCENT; ADULT; BELGIUM; BLOOD RETINA BARRIER; BODY MASS; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPLEMENT CLASSICAL PATHWAY; CONVULSION; DIABETES CONTROL; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; ELECTROENCEPHALOGRAM; ERYTHROCYTE; EXERCISE TEST; FEMORAL NERVE; GLOMERULAR DYSFUNCTION; GLYCOLYSIS; HEART RATE VARIABILITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIC COMA; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KIDNEY DISEASE; LIOTHYRONINE BLOOD LEVEL; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; METABOLIC REGULATION; MICROANEURYSM; NERVE CONDUCTION; NERVE FIBER; NEUROPATHY; NEUTROPHIL CHEMOTAXIS; ONSET AGE; OXIDATIVE STRESS; PERONEUS NERVE; PROTEINURIA; PUBERTY; RETINA FLUORESCEIN ANGIOGRAPHY; REVIEW; RISK FACTOR; SCREENING; SEX DIFFERENCE; STATISTICAL ANALYSIS; SYMPATHETIC TONE; TRAINING; TRIACYLGLYCEROL BLOOD LEVEL; WELLBEING;

ADOLESCENT; BELGIUM; CHILD; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; HUMANS; INCIDENCE; MASS SCREENING;

EID: 13444266425     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (167)

1. Dorchy H, Olinger S. Bien-être des diabétiques insulino-dépendants. Evaluation chez 100 adolescents et adultes jeunes en fonction de leur contrôle métabolique. Presse Méd 1997;26:1420-1424
2. Hoey H, Aanstoot HJ, Chiarelli F, Daneman D, Danne T, Dorchy H, Fitzgerald M, Garandeau P, Greene S, Holl RW, Hougaard P, Kaprio E, Kocova M, Lynggaard H, Martul P, Matsuura N, McGee HM, Mortensen HB, Robertson K, Schoenle E, Søvik O, Swift P, Tsou RM, Vanelli M, Åman J, for the Hvidøre Study Group on Childhood Diabetes. Good metabolic control is associated with better quality of life in 2,101 adolescents with type 1 diabetes. Diabetes Care 2001;24:1923-1928
3. Pirart J. Diabète et complications dégéné ratives. Présentation d'une étude prospective sur 4.400 cas observés entre 1947 et 1973. Diabète Métab 1977;3:97-107, 173-182, 245-256
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;29:977-986
5. Verougstraete C, Libert J, Dorchy H. Discordant diabetic retinopathy in homozygous twins: the importance of good metabolic control. J Pediatr 1999;134:658
6. Alcolado J. Genetics of diabetic complications. Lancet 1998;351:230-231
7. Kao Y, Donaghue KC, Chan A, Bennetts BH, Knight J, Silink M. Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes. Diabet Med 2002;19:212-215
8. Mogensen CE. Genetics and diabetic renal disease: still a black hole. Diabetes Care 2003;26:1631-1632
9. Dorchy H. Quel contrôle glycémique peut être obtenu chez des jeunes diabétiques sans sécrétion résiduelle d'insuline endogène? Quelle est la fréquence des hypoglycémies sévères et des complications subcliniques? Arch Pédiatr 1994;1:970-981
10. Dorchy H. Dorchy's recipes explaining the "intriguing efficacy of Belgian conventional therapy". Diabetes Care 1994;17:458-460
11. Dorchy H, Roggemans MP, Willems D. Glycated hemoglobin and related factors in diabetic children and adolescents under 18 years of age: a Belgian experience. Diabetes Care 1997;20:2-6
12. Dorchy H, Roggemans MP, Willems D. Hémoglobine glyquée chez des jeunes diabétiques de moins de 18 ans non sélectionné s. Comparaison de 2 méthodes de dosage par HPLC. Rev Méd Brux 1997;18:59-63
13. Czernichow P, Dorchy H. Traitement et insulinothérapie. In: Czernichow P, Dorchy H, eds. Diabétologie pédiatrique. Paris, Doin 1989;445-496
14. Dorchy H. Traitement du diabète de type 1 chez l'enfant et l'adolescent. Rev Praticien (Paris) 1996;46:577-586
15. Dorchy H. Insulin regimens and insulin adjustments in diabetic children, adolescents and young adults: personal experience. Diabetes Metab (Paris) 2000;26:500-507
16. Dorchy H. Choix des insulines et adaptation des doses chez les enfants et adolescents diabétiques: expérience personnelle. Rev Méd Brux 2000;21:19-27
17. Dorchy H. Sport et diabète de type 1: expérience personnelle. Rev Méd Brux 2002;23:A211-A217
18. Dorchy H. Dietary management for children and adolescents with diabetes mellitus: personal experience and recommendations. J Pediatr Endocrinol Metab 2003;16:131-148
19. Rosilio M, Cotton JB, Wielliczko MC, Gendrault B, Carel JC, Couvaras O, Ser N, Bougnéres PF, Gillet P, Soskin S, Garandeau P, Stuckens C, Le Luyer B, Jos J, Bony-Trifunovic H, Bertrand AM, Leturcq F, Lafuma A. Factors associated with glycemic control: a cross sectional nationwide study in 2,579 French children with type 1 diabetes. Diabetes Care 1998;21:1146-1153
20. Mortensen H, Hougaard P, The Hvidøre Study Group On Childhood Diabetes. Comparison of metabolic control in a cross-sectional study of 2,873 children and adolescents with IDDM from 18 countries. Diabetes Care 1997;20:714-720
21. Mortensen HB, Robertson KJ, Aanstoot H-J, Danne T, Holl RW, Hougaard P, Atchinson JA, Chiarelli F, Daneman D, Dinesen B, Dorchy H, Garandeau P, Greene S, Hoey H, Kaprio EA, Kocova M, Lynggaard H, Martul P, Matsuura N, Schoenle EJ, Søvik O, Swift P, Tsou RM, Vanelli M, Åman J, for the Hvidøre Study Group on Childhood Diabetes. Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries. Diabet Med 1998;15:752-759
22. Danne T, Mortensen HB, Hougaard P, Lynggaard H, Aanstoot HJ, Chiarelli F, Daneman D, Dinesen B, Dorchy H, Garandeau P, Greene S, Hoey H, Holl RW, Kaprio EA, Kocova M, Martul P, Matsuura N, Robertson KJ, Schoenle EJ, Søvik O, Swift PGF, Tsou RM, Vanelli M, Åman J, for The Hvidøre Study Group on Childhood Diabetes. Persistent differences among centers over 3 years in glycemic control and hypoglycemia in a study of 3,805 children and adolescents with type 1 diabetes from the Hvidøre Study Group. Diabetes Care 2001;24:1342-1347
23. Holl RW, Swift PGF, Mortensen HB, Lynggaard H, Hougaard P, Aanstoot H-J, Chiarelli F, Daneman D, Danne T, Dorchy H, Garandeau P, Greene S, Hoey H, Kaprio EA, Kocova M, Martul P, Matsuura N, Robertson KJ, Schoenle EJ, Søvik O, Tsou RM, Vanelli M, Åman J, for The Hvidøre Study Group on Childhood Diabetes. Insulin injection regimens and metabolic control in an international survey of adolescents with type 1 diabetes over 3 years: results from the Hvidøre study group. Eur J Pediatr 2003;162:22-29
24. Dorchy H. Dépistage des complications subcliniques chez les jeunes diabétiques: l'expérience bruxelloise. Ann Pédiatr (Paris) 1998;45:585-606
25. Danne T, Kordounouri O, Hovener G, Weber B. Diabetic angiopathy in children. Diabetic Med 1997;14:1012-1025
26. Dorchy H, Toussaint D. Reversal of complications of diabetes mellitus with improved metabolic control. J Pediatr 1982;100:337-338
27. Dorchy H, Loeb H. Functional abnormalities precede structural lesions in diabetic children and adolescents. Transplantation Proc 1986;18:1494-1495
28. Dorchy H. Characterization of the early stages of diabetic retinopathy: importance of the breakdown of the blood-retinal barrier. Diabetes Care 1993;16:1213-1214
29. Dorchy H, Van Vliet C, Toussaint D, Ketelbant-Balasse P, Loeb H. Mauriac syndrome: three cases with angiofluorescein study. Diabète Métab 1979;5:195-200
30. Goldstein DE, Blinder KJ, Ide CH, Wilson RJ, Wiedmeyer HM, Little RR, England JD, Eddy M, Hewett JE, Anderson RR. Glycemic control and development of retinopathy in youth-onset insulin-dependent diabetes mellitus. Ophthalmology 1993;100:1125-1132.
31. Donaghue KC, Fung ATW, Hing S, Fairchild J, King J, Chan A, Howard NJ, Silink M. The effect of prepubertal diabetes duration on diabetes. Microvascular complications in early and late adolescence. Diabetes Care 1997;20:77-80
32. Donaghue KC, Fairchild JM, Craig ME, Chan AK, Hing S, Cutler LR, Howard NJ, Silink M. Do all prepubertal years of diabetes duration contribute equally to diabetes complications? Diabetes Care 2003;26:1224-1229
33. Dorchy H, Veroustraete C, Verstappen A, De Schepper J, Haentjens M, Toussaint D. Longitudinal study on the first microangiographic abnormalities in childhood diabetes. Types of lesions and risk factors. Hormone Res 1991;35:54
34. Dorchy H, De Schepper J, Haentjens M, De Maertelaer V, Verougstraete C, Loeb H. The course of incipient diabetic retinopathy in youth -as revealed by fluorescein angiography. Pediatr Adolesc Endocrinol 1989;18:101-106
35. Williamson JR, Rowold E, Chans K, Marvel J, Tomlinson M, Sherman WR, Ackerman KE, Berger RA, Kilo C. Sex steroid dependency of diabetes-induced changes in polyol metabolism, vascular permeability and collagen cross-linking. Diabetes 1986;35:20-27
36. Moran A, Jacobs DR, Steinberger J, Hong CP, Prineas R, Luepker R, Sinaiko AR. Insulin resistance during puberty. Results from clamp studies in 357 children. Diabetes 1999;48:2039-2044
37. Weber B. Rétinopathie diabétique. In: Czernichow P, Dorchy H, eds. Diabétologie pédiatrique. Paris, Doin 1989;259-282
38. Dorchy H. Complications neurologiques. In: Czernichow P, Dorchy H, eds. Diabétologie pédiatrique. Paris, Doin 1989;307-325
39. Drummond KN. Rein et diabète. In: Czernichow P, Dorchy H, eds. Diabétologie pédiatrique. Paris, Doin 1989;283-306
40. Couper J. Microvascular complications of insulin-dependent diabetes: risk factors, screening and intervention. J Paediatr Child Health 1996;32:7-9
41. Sochett E, Daneman D. Early diabetes-related complications in children and adolescents with type 1 diabetes. Implications for screening and intervention. Endocrinol Metab Clin North Am 1999;28:865-882
42. Brink S. Complications of pediatric and adolescent type 1 diabetes mellitus. Current Diabetes Reports 2001;1:47-55
43. Chiarelli F, Mohn A, Tumini S, Trotta D, Verrotti A. Screening for vascular complications in children and adolescents with type 1 diabetes mellitus. Horm Res 2002;57(suppl 1):113-116
44. Chiarelli F, Mohn A. Angiopathy in children with diabetes. In: Brink S, Serban V, eds. Timisoara, Brumar 2003;299-324
45. ISPAD (International Society for Pediatric and Adolescent Diabetes) - Consensus guidelines 2000, Swift PGE ed. Zeist, Netherlands, Publ Medforum 2000;95-101
46. Novotny HR, Alvis DL. A method of photographing fluorescence in circulating blood in the human retina. Circulation 1961;24:82-86
47. Toussaint D, Dorchy H. Exploration angiofluorescéinique de la rétinopathie diabétique infantile: étude préliminaire. Bull Soc Belge Ophtalmol 1974;168:783-800
48. Dorchy H, Toussaint D, Devroede M, Ernould C, Loeb H. Diagnostic de la rétinopathie diabétique infantile par angiographie fluorescéinique. Description des lésions initiales. Nouv Presse Méd 1977;6:345-347
49. Dorchy H, Toussaint D, Vanderschueren-Lodeweyckx M, Vandenbussche E, Devroede M, Loeb H. Leakage of fluorescein: first sign of juvenile diabetic retinopathy. Acta Pædiatr Scand 1979; suppl. 277:47-53
50. Dorchy H, Toussaint D. Fluorescein leakage: first sign of juvenile diabetic retinopathy. Lancet 1978;1:1200
51. Dorchy H, Toussaint D. Mise en evidence d'un trouble précoce de la perméabilité des capillaries rétiniens diabétiques par angiographie fluorescéinique. In: Journées de diabétologie de l'Hôtel-Dieu. Paris, Flammarion Médecine-Sciences 1979;35-45
52. Dorchy H, Toussaint D. Rupture précoce de la barrière hémato-rétinienne chez les jeunes diabétiques. Trouble fonctionnel initial de la rétinopathie dans le diabète de type 1 chez l'enfant et l'adolescent. Rev Méd Brux 1984;5:319-331
53. Dorchy H, Toussaint D. Early breakdown of the blood-retinal barrier in diabetic children: incipient functional abnormality in diabetic retinopathy. Diabetes in the Young (Bulletin of ISGD) 1985;12:18-46
54. Dorchy H. Early diabetic retinopathy. Diabetologia 1987;30:274
55. Patz A. Retinal vascular diseases (reply to a letter). N Engl J Med 1978;299:1017-1018
56. Veroustraete C, Toussaint D, De Schepper J, Haentjens M, Dorchy H. First microangiographic abnormalities in childhood diabetes-types of lesions. Graefe's Arch Clin Exp Ophthalmol 1991;229:24-32
57. Dorchy H, Toussaint D, Verougstraete C, Lemiere B. Transient acute disc swelling associated with improved metabolic control in an adolescent with type 1 diabetes: role of dexamethazone therapy. Eur J Pediatr 1985;143:187-190
58. Daneman D, Drash A, Lobes LA, Becker DJ, Baker LM, Travis LB. Progressive retinopathy with improved control in diabetic dwarfism (Mauriac's syndrome). Diabetes Care 1981;4:360-365
59. Cunha-Vaz JC, Fonseca JR, Abreu JF, Ruas MA. Detection of early retinal changes in diabetes by vitreous fluorophotometry. Diabetes 1979;28:16-19
60. Haut J, Redor JY, Abboud E, van Effenterre G, Moulin F. Classification of diabetic retinopathy. Ophthalmologica 1987;195:145-155
61. Salardi S, Rubbi F, Puglioli R, Brancaleoni A, Bacchi-Reggiani L, Ragni L, Cacciari E. Diabetic retinopathy in childhood: long-term follow-up by fluorescein angiography beginning in the first months of disease. J Pediatr Endocrinol Metab 2001;14:507-515
62. Wardle EN. Vascular permeability in diabetics and implication for therapy. Diabetes Res Clin Pract 1994;23:135-139
63. Schmetterer L, Woltz M. Ocular blood flow and associated functional deviations in diabetic retinopathy. Diabetologia 1999;42:387-405.
64. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW. Vascular permeability in experimental diabetes is associated with reduced endothelial occluding content. Vascular endothelial growth factor decreases occluding in retinal endothelial cells. Diabetes 1998;47:1953-1959
65. Dorchy H, Toussaint D, Haumont D, Loeb H. Relationship between some clinical and biological factors and incipient diabetic retinopathy diagnosed by fluorescein angiography. Am J Ophthalmol 1983;96:108-110
66. Malone JI, Van Cader TC, Edwards WC. Diabetic vascular changes in diabetes. Diabetes, 1977;26:673-679
67. Dorchy H, Loeb H. More on "diabetic control"! What is it? J Pediatr 1977;90:502-503
68. Dorchy H, Despontin M, Haumont D, Toussaint D, De Vroede M, Loeb H. Hémoglobine glycosylée et estimation clinique du degré de contrôle du diabète. Relations avec la glycémie, la cholestérolémie, la triglycéridémie, la durée du diabète et la rétinopathie. Etude de 85 enfants et adolescents diabétiques. Ann Pédiatr 1982;29:319-326
69. Verougstraete C, Haentjens M, Dorchy H. Analyse de la micro-angiopathie des jeunes diabétiques par l'angiographie rétinienne. Relations avec la durée du diabète, l'HbA1, les antigènes HLA-DR et la neuropathie. J Fr Ophtalmol 1986;9:665-666
70. Dorchy H, Roggemans MP, Willems D. Quel contrôle glycémique peut être obtenu chez des jeunes diabétiques et quelle est la fréquence des complications subcliniques? Avec 4 ans de recul supplémentaire. Arch Pédiatr 1996;3:294-296
71. Dorchy H, Claes C, Verougstraete C. Risk factors of developing proliferative retinopathy in type 1 diabetic patients. Role of BMI. Diabetes Care 2002;25:798-799
72. Zangh L, Krentowski G, Albert A, Lefebvre P. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 2001;24:1275-1279
73. Haumont D, Dorchy H, Pelc S. EEG abnormalities in diabetic children. Influence of hypoglycemia and vascular complications. Clin Pediatr 1979;18:750-753
74. Hauser E, Strohmayer C, Seidl R, Birnbacher R, Lischka A, Schober E. Quantitative EEG in young diabetics. J Child Neurol. 1995;10:330-334
75. Bjorgaas M, Sand T, Gimse R. Quantitative EEG in type 1 diabetic children with and without episodes of severe hypoglycemia: a controlled, blind study. Acta Neurol Scand 1996;93:398-402
76. Biessels GJ, Kappelle AC, Bravenboer B, Erkelens DW, Gispen WH. Cerebral function in diabetes mellitus. Diabetologia 1994;37:643-650
77. Noël P, Dorchy H, Loeb H. Neurophysiological evaluation of subclinical neuropathy in juvenile diabetes. Pediatr Adolesc Endocrinol 1981;9:130-139
78. Barkai L, Kempler P, Vamosi I, Lukacs K, Marton A, Keresztes K. Peripheral sensory nerve dysfunction in children and adolescents with type 1 diabetes mellitus. Diabet Med 1998;15:128-133
79. Dorchy H, Noël P, Krüger M, De Maertelaer V, Dupont D, Toussaint D, Pelc S. Peroneal motor nerve conduction velocity in diabetic children and adolescents. Relationship to metabolic control, HLA-DR antigens, retinopathy and EEG. Eur J Pediatr 1985;144:310-315
80. Krüger M, Brunko E, Dorchy H, Noël P. Femoral versus peroneal neuropathy in diabetic children and adolescents. Relationships to clinical status, metabolic control and retinopathy. Diabète Métab 1987;13:110-115
81. Carrington AL, Shaw JE, Van Schie CH, Abbott CA, Vileikyte L, Boulton AJ. Can motor nerve conduction velocity predict foot problems in diabetic subjects over a 6-year outcome period? Diabetes Care 2002;25:2010-2015
82. Bril V, Ngo M. Limits of the sympathetic skin response in patients with diabetic polyneuropathy. Muscle Nerve 2000;23:1427-1430
83. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003;26:1553-1579
84. Kandel K, Rondia G, Dorchy H. Cardiac autonomic neuropathy in type 1 diabetic patients: diagnosis by statistic and spectral analyzis of heart rate variability. J Pediatr Endocrinol Metab 2001;14(suppl 3):1072
85. Massin MM, Derkenne B, Tallsund M, Rocour-Brumioul D, Ernould C, Lebrethon M-C, Bourguignon J-P. Cardiac autonomic dysfunction in diabetic children. Diabetes Care 1999;22:1845-1850
86. Riihimaa PH, Suominen K, Jantti V, Knip M, Tapanainen P, Tolonen U. Cardiovascular autonomic reactivity is decreased in adolescents with type 1 diabetes. Diabet Med 2002;19:932-938
87. Anderson AR, Sandahl CJ, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in type 1 (insulin-dependent diabetes: an epidemiological study. Diabetologia 1983;25:496-501
88. Arun CS, Stoddart J, Mackin P, MacLeod JM, New JP, Marshall SM. Significance of microalbuminuria in long-duration type 1 diabetes. Diabetes Care 2003;26:2144-2149.
89. Cambier P. Application de la théorie de Rehberg à l'étude clinique des affections rénales et du diabète. Ann Méd 1934;35:273-299
90. Soper CPR, Barron JL, Hyer SL. Long-term glycaemic control directly correlates with glomerular filtration rate in early type 1 diabetes mellitus before the onset of microalbuminuria. Diabet Med 1998;15:1010-1014
91. Dorchy H. Néphropathie diabétique: évolution naturelle, diagnostic précoce, prévention. CR Soc Belge Pédiatr 1992;24(4):11-20
92. Mogensen CE, Vittinghus E. Urinary albumin excretion during exercise in juvenile diabetes. A provocation test for early abnormalities. Scand J Clin Lab Invest 1975;35:295-300
93. Poortmans J, Dewancker A, Dorchy H. Urinary excretion of total protein, albumin and β2-microglobulin during exercise in adolescent diabetics. Biomedicine Express 1976;25:273-274
94. Poortmans J, Dorchy H, Toussaint D. Urinary excretion of total proteins, albumin and β2-microglobulin during rest and exercise in diabetic adolescents with and without retinopathy. Diabetes Care 1982;5:617-623
95. Poortmans JR, Dorchy H. Exercise, kidney responses and diabetes. In: Kawamori R, Vranic M, Norton ES, Kubota M., eds. Glucose fluxes, exercise and diabetes. Great Britain, Smith-Gordon 1995;85-90
96. Poortmans JR, Waterlot B, Dorchy H. Training effect on postexercise microproteinuria in type 1 diabetic adolescents. Pediatr Adolesc Endocrinol 1988;17:166-172
97. Bernard AM, Ouled A, Goemare-Vanneste J, Antione JL, Lauwerys RR, Lambert A, Vandeleene B. Microtransferrinuria is a more sensitive indicator of early glomerular damage in diabetes than micro-albuminuria. Clin Chem 1988;34:1920-1921
98. Poortmans J, Dorchy H, De Maertelaer V. Subclinical proteinuria in type 1 diabetic children and adolescents: relationship to duration of diabetes, metabolic control, HLA-DR type, retinopathy and neuropathy. Diabetic Nephropathy 1984;3:123-126
99. Carlier L, Willems D, Dorchy H. Would increased urine transferrin excretion be a predictive marker of early glomerular dysfunction in type 1 young diabetic patients? J Pediatr Endocrinol Metab 2001;14(suppl 3):1072
100. Poortmans JR, Dorchy H. Would acid aminoglycans be a predictive marker of early glomerular dysfunction in type 1 young diabetic patients? J Pediatr Endocrinol Metab 2001;14(suppl 3):1072
101. Hong CY, Chia KS. Markers of diabetic nephropathy. J Diabetes Complications 1998;12:43-60.
102. Kordonouri O, Kahl A, Jörres A, Hopfenmüller W, Danne T. The prevalence of incipient tubular dysfunction, but not glomerular dysfunction, is increased in patients with diabetes onset in childhood. J Diabetes Complications 1999;13:320-324
103. Schultz CJ, Neil HAW, Dalton RN, Dunger DB. Risk of nephropathy can be detected before the onset of microalbuminuria during the early years after diagnosis of type 1 diabetes. Diabetes Care 2000;23:1811-1815
104. Warram JH, Scott LJ, Hanna LS, Wantman M, Cohen SE, Laffel LMB, Ryan L, Krolewski AS. Progression of microalbuminuria to proteinuria in type 1 diabetes. Nonlinear relationship with hyperglycemia. Diabetes 2000;49:94-100
105. Koren W, Koldanov R, Pronin VS, Postnov IY, Petes E, Rosenthal T, Berezin M, Postnov YV. Enhanced erythrocyte Na+/H+ exchange predicts diabetic nephropathy in patients with IDDM. Diabetologia 1998;41:201-205
106. Andersen S, Tarnow L, Cambien F, Rossing P, Juhl T, Deinum J, Parving HH. Long-term renoprotective effects of losartan in diabetic nephropathy. Diabetes Care 2003;26:1501-1506
107. Haffner SM. Lipoprotein (a) and diabetes: an update. Diabetes Care 1993;16:835-840
108. Couper JJ, Bates DJ, Cocciolone R, Magarey AM, Boulton TJC, Penfold JL, Ryall RC. Association of lipoprotein (a) with puberty in IDDM. Diabetes Care 1993;16:869-873
109. Willems D, Dorchy H, Dufrasne D. Serum lipoprotein (a) in type 1 diabetic children and adolescents: relationships with HbA1c and subclinical complications. Eur J Pediatr 1996;155:175-178
110. Hernandez C, Chacon P, Garcia-Pascual L, Simo R. Differential influence of LDL cholesterol and triglycerides on lipoprotein(a) concentrations in diabetic patients. Diabetes Care 2001;24:350-355
111. Koschinsky ML, Marcovina SM. The relationship between lipoprotein(a) and the complications of diabetes mellitus. Acta Diabetol 2003;40:65-76
112. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843
113. Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager AM, Doni A, van Hinsbergh VW, Stehouwer CD. Plasma concentration of C-reactive protein is increased in type 1 diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999;42:351-357
114. Dorchy H, Coulon B, Willems D. Increased levels of ultra sensitive CRP in young type 1 diabetic patients with or without subclinical complications. J Pediatr Endocrinol Metab 2002;15(suppl 4):1063
115. American Diabetes Association. Management of dyslipidemia in children with diabetes. Diabetes Care 2003;26:2194-2197
116. Willems D, Dorchy H. Taux des lipoprotéines et des apoliprotéines chez les jeunes diabétiques insulinodé pendants. Relations avec l'hémoglobine glycosylée et la fructosamine. Presse Méd 1990;19:17-20
117. Willems D, Dorchy H. Sous-fractions du HDL-cholestérol chez les jeunes diabétiques insulinodépendants. Presse Méd 1991;20:86
118. Donaghue KC, Pena MM, Chan AKF, Blades BL, King J, Storlein LH, Silink M. Beneficial effects of increasing monounsaturated fat intake in adolescents with type 1 diabetes. Diabetes Res Clin Pract 2000;48:193-199
119. Tomkin GH, Owens D. Abnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis. Diabetes Metab Res Rev 2001;17:27-43
120. Abraha A, Schultz C, Konopelska-Bahu T, James T, Watts A, Stratton IM, Matthews DK, Dunger DB. Glycaemic control and familial factors determine hyperlipidaemia in early childhood diabetes. Oxford Regional Prospective Study of Childhood Diabetes. Diabet Med 1999;16:598-604
121. West IC. Radicals and oxidative stress in diabetes. Diabet Med 2000;17:171-180
122. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 2003;26:1589-1596
123. Ndahimana J, Dorchy H, Vertongen F. Activité anti-oxydante érythrocytaire et plasmatique dans le diabète de type 1. Presse Méd 1996;25:188-192
124. Dorchy H, Ndahimana J, Vertongen F. Erythrocyte and plasma antioxidant activity and subclinical complications in young diabetic patients. Diabetes Care 1996;19:1165
125. Dorchy H. Lower plasma vitamin C levels in young type 1 diabetic patients with microalbuminuria. J Diabetes Complications 1999;13:119
126. Hirsch JB, Atchley DH, Tsai E, Labbé RF, Chait A. Ascorbic acid clearance in diabetic nephropathy. J Diabetes Complications 1998;12:259-263
127. Sytze van Dam P. Oxidative stress and diabetic neuropathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2002;18:176-184.
128. Dominguez C, Ruiz E, Gussinye M, Carrascoa A. Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents. Diabetes Care 1998;21:1736-1742
129. Willems D, Dorchy H, Dufrasne D. Serum antioxidant status and oxidized LDL in well-controlled young type 1 diabetic patients with and without subclinical complications. Atherosclerosis 1998;137(suppl):S61-S64
130. Varvarovska J, Racek J, Stozicky F, Soucek J, Trefil L, Pomahacova R. Parameters of oxidative stress in children with Type 1 diabetes mellitus and their relatives. J Diabetes Complications 2003;17:7-10
131. Ditzel J. Oxygen transport impairment in diabetes. Diabetes 1976;25:832-838
132. Cauchie P, Vertongen F, Bosson D, Dorchy H. Erythrocyte metabolic alterations in type 1 diabetes: relationship to metabolic control. Ann Biol Clin 1992;50:9-13
133. Dorchy H, Cantinieaux B, De Maertelaer V, Hariga C, Mascart F, Fondu P. Granulocyte functions in non-acidotic juvenile diabetes: evidence of a stimulating effect of plasma protein glycosylation. Diabetes in the Young (Bulletin of ISGD)1992;28:11-14
134. Dorchy H, Lemiere B, Toussaint D, Gausset P. Anticorps anti-cellules des îlots de Langerhans et spécifiques d'organes chez les jeunes diabétiques. Relations avec l'âge, le début et la durée du diabète, la sécrétion résiduelle d'insuline endogène et la rétinopathie. Nouv Presse Méd 1981:10:2795-2798
135. Dorchy H, Bourdoux P, Lemiere B. Subclinical thyroid hormone abnormalities in type 1 diabetic children and adolescents. Relatioships to metabolic control. Acta Paediatr Scand 1985;74:386-389
136. Radetti G, Paganini C, Gentili L, Barbin F, Pasquino B, Zachmann M. Altered adrenal and thyroid function in children with insulin-dependent diabetes mellitus. Acta Diabetol 1994:31:138-140
137. Kordonouri O, Deiss D, Danne T, Dorow A, Bassir C, Gruters-Kieslich A. Predictivity of thyroid autoantibodies for the development of thyroid disorders in children and adolescents with type 1 diabetes. Diabet Med 2002;19:518-521
138. Dorchy H, Declercq S, Willems D. Decreased magnesium levels in serum and erythrocytes of young type 1 diabetic subjects. Relationships with glycated hemoglobin levels (HbA1c) and subclinical complications. Diabetes Res Clin Pract 1999;44:S27
139. De Valk HW, Hardus P, Van Rijn H, Ekelens D. Plasma magnesium concentration and progression of retinopathy. Diabetes Care 1999;22:864-865
140. Djurhuus MS, Skott P, Vaag A, Hother-Nielsen O andersen P, Parving HH, Klitgaard NA. Hyperglycaemia enhances renal magnesium excretion in type 1 diabetic patients. Scand J Clin Lab Invest 2000;60:403-409
141. Megraud F, Brassens-Rabbé MP, Denis F, Belbouri A, Hoa DQ. Seroepidemiology of Campylobacter pylori infection in various populations. J Clin Microbiol 1989;27:1870-1873
142. Oldenburg B, Diepersloot RJA, Hoekstra JBL. High seroprevalence of helicobacter pylori in diabetes mellitus patients. Dig Dis Sc 1996;41:458-461
143. Scaillon M, Bontems P, Dorchy H, Cadranel S. Infection à Helicobacter Pylori chez les jeunes diabétiques: prevalence chez les caucasiens européens et maghrébins résidant en Belgique. CR Soc Belge Pédiatr (Mini Acta) 1997;29:112
144. Arslan D, Kendirci M, Kurtoglu S, Kula M. Helicobacter pylori infection in children with insulin dependent diabetes mellitus. J Pediatr Endocrinol Metab 2000;13:553-556
145. Scaillon M, Dorchy H, Cadranel S. Relationship between glycated haemoglobin (HbA1c) and eradication of Helicobacter Pylori (HP) infection in young type 1 diabetic patients. Diabetes Res Clin Pract 1999;44:S28
146. de Luis DA, Cordero JM, Caballero C, Boixeda D, Aller R, Canton R, de la Calle H. Effect of the treatment of Helicobacter pylori infection on gastric emptying and its influence on the glycaemic control in type 1 diabetes mellitus. Diabetes Res Clin Pract 2001;52:1-9
147. Ojetti V, Pitocco D, Bartolozzi F, Danese S, Migneco A, Lupascu A, Pola P, Ghirlanda G, Gasbarrini G, Gasbarrini A. High rate of helicobacter pylori re-infection in patients affected by type 1 diabetes. Diabetes Care 2002;25:1485
148. Dorchy H, Duchateau J, D'Hooge D. Normalization of complement activation and consumption in diabetic children and adolescents after switch-over from porcine to semisynthetic human insulin. Diabète Métab 1988;14:415-421
149. Dorchy H, Duchateau J, Bosson D, D'Hooge D. Transfer from porcine insulins to semisynthetic human insulins decreases insulin antibodies and circulating immune complexes in diabetic children and adolescents? A two year follow-up. Diabète Métab 1989;15:107-110.
150. Duchateau J, Schreyen H, Dorchy H. Intermediate and long-acting preparations without protamine sulphate are complement activators in vitro. Diabète Métab 1992;18:272-276
151. Duchateau J, Schreyen H, Dorchy H. Lack of in vitro complement activation by the human insulin analogue LYS (B28) PRO (B29). Diabète Métab 1994;20;562-563
152. Dorchy H. Le stylo-injecteur d'insuline chez le jeune diabétique: liberté et prise pondérale excessive. Pédiatrie 1988;43:697-702
153. Bradley C, Gamsu DS for the Psychological Well-being Working Group of the WHO/IDF St Vincent Declaration Action Programme for Diabetes. Guidelines for encouraging psychological well-being; Diabet Med 1994;11:510-516
154. Dorchy H. Improving outcomes for young people with diabetes. Diabet Med 2002;19:702-703
155. Levine BS Anderson BJ, Butler DA, Antisdel JE, Brackett J, Laffel LM. Predictors of glycemic control and short-term adverse outcomes in youth with type 1 diabetes. J Pediatr 2001;139:174-176
156. Dabadghao P, Vidmar S, Cameron FJ. Deteriorating diabetic control through adolescence-do the origins lie in childhood? Diabet Med 2001;18:889-94
157. Litton J, Rice A, Friedman N, Oden J, Lee MM, Freemark M. Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr 2002;141:490-495
158. Barton DM, Baskar V, Kamalakannan D, Buch HN, Gone K, Wilson E , Anderson J, Abdu TA. An assessment of care of paediatric and adolescent patients with diabetes in a large district general hospital. Diabet Med 2003;20:394-398
159. Weintrob N, Benzaquen H, Galatzer A, Shalitin S, Lazar L, Fayman G, Lilos P, Dickerman Z, Phillip M. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Pediatrics 2003;112:559-564
160. Cavallerano AA, Cavallerano JD, Katalinic P, Tolson AM, Aiello LP, Aiello LM; Joslin Vision Network Clinical Team. Use of Joslin Vision Network digital-video nonmydriatic retinal imaging to assess diabetic retinopathy in a clinical program. Retina. 2003;23:215-223
161. Tennant MT, Rudnisky CJ, Hinz BJ, MacDonald IM, Greve MD. Tele-ophthalmology via stereoscopic digital imaging: a pilot project. Diabetes Technol Ther 2000;2:583-587
162. Infante JR, Rosenbloom AL, Silverstein JH, Garzarella L, Pollock BH. Changes in frequency and severity of limited joint mobility in children with type 1 diabetes mellitus between 1976-78 and 1998. J Pediatr 2001;138:33-37
163. Laron Z, Galatzer A, Amir S, Gil R, Karp M, Mimouni M. A multidisciplinary, comprehensive, ambulatory treatment scheme for diabetes mellitus in children. Diabetes Care 1979;4:342-348
164. Lemiere B, Goethals D, Dorchy H, Loeb H. Medico-social profile of a pediatric Diabetology unit. Pediatr Adolesc Endocrinol 1982;10:192-197.
165. Brink SJ, Miller M, Moltz K. Education and multidisciplinary team care concepts for pediatric and adolescent diabetes mellitus. J Pediatr Adolesc Endocrinol 2002;15:1113-1130
166. Dorchy H, Ernould C. Les colonies de vacances pour enfants et adolescents diabétiques. Diabète Métab (Paris) 1990;16:513-521
167. Dorchy H. (R)évolution de la diabétologie pédiatrique et optimisation du traitement. Ann Pédiatr (Paris) 1998;45:521-529